187 related articles for article (PubMed ID: 32959428)
1. Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
Cappellini A; Mongiorgi S; Finelli C; Fazio A; Ratti S; Marvi MV; Curti A; Salvestrini V; Pellagatti A; Billi AM; Suh PG; McCubrey JA; Boultwood J; Manzoli L; Cocco L; Follo MY
FASEB J; 2020 Nov; 34(11):15400-15416. PubMed ID: 32959428
[TBL] [Abstract][Full Text] [Related]
2. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Inositide Signaling Via Phospholipase C.
Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
5. K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway.
Poli A; Faenza I; Chiarini F; Matteucci A; McCubrey JA; Cocco L
Cell Cycle; 2013 Jun; 12(11):1713-21. PubMed ID: 23656785
[TBL] [Abstract][Full Text] [Related]
6. Modulation of nuclear PI-PLCbeta1 during cell differentiation.
Cocco L; Manzoli L; Faenza I; Ramazzotti G; Yang YR; McCubrey JA; Suh PG; Follo MY
Adv Biol Regul; 2016 Jan; 60():1-5. PubMed ID: 26525203
[TBL] [Abstract][Full Text] [Related]
7. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
9. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes.
Cocco L; Finelli C; Mongiorgi S; Clissa C; Russo D; Bosi C; Quaranta M; Malagola M; Parisi S; Stanzani M; Ramazzotti G; Mariani GA; Billi AM; Manzoli L; Follo MY
J Leukoc Biol; 2015 Nov; 98(5):769-80. PubMed ID: 25977289
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
11. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
14. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
15. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
17. Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).
Poli A; Ratti S; Finelli C; Mongiorgi S; Clissa C; Lonetti A; Cappellini A; Catozzi A; Barraco M; Suh PG; Manzoli L; McCubrey JA; Cocco L; Follo MY
FASEB J; 2018 Feb; 32(2):681-692. PubMed ID: 28970249
[TBL] [Abstract][Full Text] [Related]
18. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
19. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
20. A role for PLCβ1 in myotonic dystrophies type 1 and 2.
Faenza I; Blalock W; Bavelloni A; Schoser B; Fiume R; Pacella S; Piazzi M; D'Angelo A; Cocco L
FASEB J; 2012 Jul; 26(7):3042-8. PubMed ID: 22459146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
